NIH Weekly Funding Opportunities and Policy Notices

Monday, April 1, 2024 - 2:52am
Funding Opportunity PAR-24-172 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO which utilizes an R61/R33 phased approach.
Sunday, March 31, 2024 - 11:41pm
Funding Opportunity RFA-AI-24-021 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacteriaceae (CRE), and multidrug-resistant Pseudomonas aeruginosa.
Sunday, March 31, 2024 - 11:39pm
Funding Opportunity RFA-DK-24-002 from the NIH Guide for Grants and Contracts. The main objective of this NOFO is to foster development and testing of technologies adaptable to aging-related changes in older adults (aged 65 years or older) with T1D to improve diabetes management and quality of life. Older adults may have increased vulnerability to hypoglycemia, cognitive impairment and/or multiple co-morbidities which may affect the risks and benefits of these technologies in this population. Projects will be funded to a) develop and test new technologies and b) to adapt and test existing technologies. It is expected that aging-adaptive diabetes technologies that address barriers for use among older adults with T1D will improve usability, adoption and adherence decreasing the risk of hypoglycemia (and hypoglycemia unawareness) while enhancing glycemic control, facilitating better diabetes management, and improving quality of life for these individuals and their caregivers.
Sunday, March 31, 2024 - 11:37pm
Notice NOT-MH-24-216 from the NIH Guide for Grants and Contracts
Sunday, March 31, 2024 - 11:35pm
Notice NOT-MH-24-215 from the NIH Guide for Grants and Contracts
Sunday, March 31, 2024 - 11:34pm
Notice NOT-MH-24-235 from the NIH Guide for Grants and Contracts
Friday, March 29, 2024 - 8:41am
Notice NOT-EB-24-001 from the NIH Guide for Grants and Contracts
Friday, March 29, 2024 - 12:53am
Funding Opportunity PA-24-205 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to build evidence about the characteristics and value of primary care that influence patient outcomes and advance health equity, such as care coordination, continuity of care, and comprehensiveness of care, person-centered, whole healthcare, and trust, and how these can be improved and effectively delivered to strengthen primary healthcare.
Thursday, March 28, 2024 - 8:53am
Funding Opportunity RFA-HL-26-001 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Career Pathway to Independence in Blood Science Award for Physician Scientists (R00) is to increase and maintain a strong cohort of new and talented, NHLBI supported, independent investigators in blood science. This program is designed to facilitate a timely transition of outstanding blood science researchers with a clinical doctorate degree from mentored research positions to independent, tenure-track or equivalent faculty positions. This NOFO offers the opportunity for current RFA-HL-20-001 or RFA-HL-20-002 K99 awardees to apply for the independent phase (R00) of the program. In the R00 phase, successful blood science physician scientist scholars will receive up to three years of funding to continue their research activity with support from this FOA, which will require updated research plans and a limited competition review.
Thursday, March 28, 2024 - 8:05am
Funding Opportunity RFA-AI-24-018 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support research to identify and characterize the interaction between hormone therapy and antiretroviral drugs (ARVs) used for treatment and prevention of HIV and co-infections.
Thursday, March 28, 2024 - 8:05am
Funding Opportunity RFA-AI-24-009 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support investigators who will form large, electronically-generated cohorts in Latin America of HIV-negative men who have sex with men (MSM), transgender women (TGW), people who inject drugs (PWID), and/or female sex-workers and follow them to study the epidemiology of HIV incidence. Continued follow-up of those persons who acquire HIV will be required to study the epidemiology of viral suppression. Comparisons of participants by seroconverstion status will provide information on geographic and socially defined areas of high HIV incidence as well as on both personal and structural vulnerabilities to HIV infection. Among participants who seroconvert, comparisons of those becoming rapidly engaged in care and who reach non-detectable HIV levels to those whose virus remains detectable will inform on the treatment of HIV in Latin American countries. This NOFO will allow digital trials to determine optimal study approaches, or to pilot evidence-based digital (mHealth and online) HIV prevention and treatment interventions to both reduce HIV incidence and improve treatment in the most vulnerable populations.
Thursday, March 28, 2024 - 7:58am
Funding Opportunity RFA-NS-24-034 from the NIH Guide for Grants and Contracts. The purpose of this Alzheimers Disease-Related Dementia (ADRD) initiative is to promote the development and distribution of innovative technologies, methods, protocols, and biomedical materials that enhance combined human neuropathology and neuroimaging research with data aimed at understanding the underlying pathophysiology of in vivo imaging results typically associated with vascular contributions to cognitive impairment and dementia (VCID) in TBI-related dementia and other ADRD diagnoses. Resources developed under this FOA must follow open data sharing practices and are intended to expand the broader research communitys capacity to perform research aimed at neuropathologically-informed understanding of the vascular pathophysiology of clinically-relevant, in vivo neuroimaging findings.
Thursday, March 28, 2024 - 7:46am
Notice NOT-DK-24-003 from the NIH Guide for Grants and Contracts
Wednesday, March 27, 2024 - 11:16pm
Funding Opportunity PAR-24-138 from the NIH Guide for Grants and Contracts. The goal of the Maximizing Access to Research Careers (MARC) program is to: Strengthen research training environments, and Promote broader participation in the biomedical research workforce by expanding the pool of well-trained scientists (for example, encouraging the inclusion of individuals from underrepresented groups) who: Complete their baccalaureate degree, and Transition into and complete biomedical, research-focused higher degree programs (such as Ph.D. or M.D./Ph.D.). Specifically, this funding announcement provides support to eligible, domesticorganizations to develop and implement effective, evidence-informed approaches to biomedical undergraduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the nation. This program is limited to applications from baccalaureate degree-granting research-intensive organizations (that is, those with NIH Research Project Grant (RPG) funding averaging greater than or equal to $7.5 million in total costs (direct and F and A/indirect) per year over the last three fiscal years (FY)).